Page last updated: 2024-08-24

aripiprazole and Ache

aripiprazole has been researched along with Ache in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's0 (0.00)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Bhat, V; Diep, C; Frey, BN; Gandhi, W; Kennedy, SH; Khoo, Y; Ladha, KS; Lam, RW; Lou, W; Milev, RV; Ravindran, AV; Rosenek, N; Rotzinger, S; Salomons, T; van Reekum, CM1
Kusnir, D; LoPiccolo, M; Sandoz, A; Tausk, FA1
Calabrese, JR; Carlson, BX; Carson, WH; Keck, PE; Marcus, RN; McQuade, RD; Rollin, LM; Sanchez, R1

Reviews

1 review(s) available for aripiprazole and Ache

ArticleYear
A clinical paradigm of delusions of parasitosis.
    Journal of the American Academy of Dermatology, 2008, Volume: 59, Issue:4

    Topics: Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Diagnosis, Differential; Female; Humans; Metabolic Syndrome; Middle Aged; Olanzapine; Pain; Patient Compliance; Peripheral Nervous System Diseases; Piperazines; Quinolones; Schizophrenia, Paranoid; Skin Diseases, Parasitic; Sleep Wake Disorders

2008

Trials

2 trial(s) available for aripiprazole and Ache

ArticleYear
Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report.
    Psychiatry research, 2022, Volume: 312

    Topics: Antidepressive Agents; Aripiprazole; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Escitalopram; Humans; Pain; Pain Measurement; Treatment Outcome

2022
A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.
    The Journal of clinical psychiatry, 2006, Volume: 67, Issue:4

    Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cross-Cultural Comparison; Double-Blind Method; Female; Humans; International Cooperation; Male; Pain; Piperazines; Placebos; Psychiatric Status Rating Scales; Quinolones; Secondary Prevention; Time Factors; Treatment Outcome

2006